COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • August 9th, 2016 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into as of June 6, 2016, by and among Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Company”), and Takeda Pharmaceutical Company Limited, a Japanese corporation (“Purchaser”).
LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED AND ULTRAGENYX PHARMACEUTICAL INC. JUNE 6, 2016License and Collaboration Agreement • August 9th, 2016 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”) is made as of the 6th day of June, 2016 (the “Execution Date”) by and between Takeda Pharmaceutical Company Limited, a company incorporated under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”), and Ultragenyx Pharmaceutical Inc., a company incorporated under the laws of California, having its principal place of business at 60 Leveroni Court, Novato, CA 94949, United States (“Ultragenyx”). Ultragenyx and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
